Literature DB >> 24578576

Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma.

Joshua N Honeyman1, Elana P Simon, Nicolas Robine, Rachel Chiaroni-Clarke, David G Darcy, Irene Isabel P Lim, Caroline E Gleason, Jennifer M Murphy, Brad R Rosenberg, Lydia Teegan, Constantin N Takacs, Sergio Botero, Rachel Belote, Soren Germer, Anne-Katrin Emde, Vladimir Vacic, Umesh Bhanot, Michael P LaQuaglia, Sanford M Simon.   

Abstract

Fibrolamellar hepatocellular carcinoma (FL-HCC) is a rare liver tumor affecting adolescents and young adults with no history of primary liver disease or cirrhosis. We identified a chimeric transcript that is expressed in FL-HCC but not in adjacent normal liver and that arises as the result of a ~400-kilobase deletion on chromosome 19. The chimeric RNA is predicted to code for a protein containing the amino-terminal domain of DNAJB1, a homolog of the molecular chaperone DNAJ, fused in frame with PRKACA, the catalytic domain of protein kinase A. Immunoprecipitation and Western blot analyses confirmed that the chimeric protein is expressed in tumor tissue, and a cell culture assay indicated that it retains kinase activity. Evidence supporting the presence of the DNAJB1-PRKACA chimeric transcript in 100% of the FL-HCCs examined (15/15) suggests that this genetic alteration contributes to tumor pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24578576      PMCID: PMC4286414          DOI: 10.1126/science.1249484

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  38 in total

1.  Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal.

Authors:  Jianjiong Gao; Bülent Arman Aksoy; Ugur Dogrusoz; Gideon Dresdner; Benjamin Gross; S Onur Sumer; Yichao Sun; Anders Jacobsen; Rileen Sinha; Erik Larsson; Ethan Cerami; Chris Sander; Nikolaus Schultz
Journal:  Sci Signal       Date:  2013-04-02       Impact factor: 8.192

Review 2.  Fibrolamellar hepatocellular carcinoma in children and adolescents.

Authors:  Howard M Katzenstein; Mark D Krailo; Marcio H Malogolowkin; Jorge A Ortega; Wenchun Qu; Edwin C Douglass; James H Feusner; Marleta Reynolds; John J Quinn; Kurt Newman; Milton J Finegold; Joel E Haas; Martha G Sensel; Robert P Castleberry; Laura C Bowman
Journal:  Cancer       Date:  2003-04-15       Impact factor: 6.860

3.  Analysis and design of RNA sequencing experiments for identifying isoform regulation.

Authors:  Yarden Katz; Eric T Wang; Edoardo M Airoldi; Christopher B Burge
Journal:  Nat Methods       Date:  2010-11-07       Impact factor: 28.547

4.  Epidermal growth factor receptor expression and gene copy number in fibrolamellar hepatocellular carcinoma.

Authors:  Anne F Buckley; Lawrence J Burgart; Sanjay Kakar
Journal:  Hum Pathol       Date:  2006-04       Impact factor: 3.466

5.  The RIalpha subunit of protein kinase A (PKA) binds to Grb2 and allows PKA interaction with the activated EGF-receptor.

Authors:  G Tortora; V Damiano; C Bianco; G Baldassarre; A R Bianco; L Lanfrancone; P G Pelicci; F Ciardiello
Journal:  Oncogene       Date:  1997-02-27       Impact factor: 9.867

6.  Cytogenetic aberrations in primary and recurrent fibrolamellar hepatocellular carcinoma detected by comparative genomic hybridization.

Authors:  L Wilkens; M Bredt; P Flemming; S Kubicka; J Klempnauer; H Kreipe
Journal:  Am J Clin Pathol       Date:  2000-12       Impact factor: 2.493

7.  Protein kinase A-dependent synergism between GATA factors and the nuclear receptor, liver receptor homolog-1, regulates human aromatase (CYP19) PII promoter activity in breast cancer cells.

Authors:  Marie France Bouchard; Hiroaki Taniguchi; Robert S Viger
Journal:  Endocrinology       Date:  2005-08-18       Impact factor: 4.736

8.  Clinicopathologic characteristics and survival outcomes of patients with fibrolamellar carcinoma: data from the fibrolamellar carcinoma consortium.

Authors:  Celina S Ang; R Katie Kelley; Michael A Choti; David P Cosgrove; Joanne F Chou; David Klimstra; Michael S Torbenson; Linda Ferrell; Timothy M Pawlik; Yuman Fong; Eileen M O'Reilly; Jennifer Ma; Joseph McGuire; Gandhi P Vallarapu; Ann Griffin; Francesco Stipa; Marinela Capanu; Ronald P Dematteo; Alan P Venook; Ghassan K Abou-Alfa
Journal:  Gastrointest Cancer Res       Date:  2013-01

9.  Differential expression analysis for sequence count data.

Authors:  Simon Anders; Wolfgang Huber
Journal:  Genome Biol       Date:  2010-10-27       Impact factor: 13.583

10.  The mutational landscape of adenoid cystic carcinoma.

Authors:  Allen S Ho; Kasthuri Kannan; David M Roy; Luc G T Morris; Ian Ganly; Nora Katabi; Deepa Ramaswami; Logan A Walsh; Stephanie Eng; Jason T Huse; Jianan Zhang; Igor Dolgalev; Kety Huberman; Adriana Heguy; Agnes Viale; Marija Drobnjak; Margaret A Leversha; Christine E Rice; Bhuvanesh Singh; N Gopalakrishna Iyer; C Rene Leemans; Elisabeth Bloemena; Robert L Ferris; Raja R Seethala; Benjamin E Gross; Yupu Liang; Rileen Sinha; Luke Peng; Benjamin J Raphael; Sevin Turcan; Yongxing Gong; Nikolaus Schultz; Seungwon Kim; Simion Chiosea; Jatin P Shah; Chris Sander; William Lee; Timothy A Chan
Journal:  Nat Genet       Date:  2013-05-19       Impact factor: 38.330

View more
  164 in total

1.  Building a staircase to precision medicine for biliary tract cancer.

Authors:  Nataliya Razumilava; Gregory J Gores
Journal:  Nat Genet       Date:  2015-09       Impact factor: 38.330

2.  Genomic spectra of biliary tract cancer.

Authors:  Hiromi Nakamura; Yasuhito Arai; Yasushi Totoki; Tomoki Shirota; Asmaa Elzawahry; Mamoru Kato; Natsuko Hama; Fumie Hosoda; Tomoko Urushidate; Shoko Ohashi; Nobuyoshi Hiraoka; Hidenori Ojima; Kazuaki Shimada; Takuji Okusaka; Tomoo Kosuge; Shinichi Miyagawa; Tatsuhiro Shibata
Journal:  Nat Genet       Date:  2015-08-10       Impact factor: 38.330

Review 3.  Protein kinase A defects and cortisol-producing adrenal tumors.

Authors:  Mihail Zilbermint; Constantine A Stratakis
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2015-06       Impact factor: 3.243

4.  An Isoform-Specific Myristylation Switch Targets Type II PKA Holoenzymes to Membranes.

Authors:  Ping Zhang; Feng Ye; Adam C Bastidas; Alexandr P Kornev; Jian Wu; Mark H Ginsberg; Susan S Taylor
Journal:  Structure       Date:  2015-08-13       Impact factor: 5.006

5.  TP53 germline and somatic mutations in a patient with fibrolamellar hepatocellular carcinoma.

Authors:  Raissa C Andrade; Maria A F D de Lima; Paulo A S de Faria; Fernando R Vargas
Journal:  Fam Cancer       Date:  2018-01       Impact factor: 2.375

Review 6.  Targeting cancer with kinase inhibitors.

Authors:  Stefan Gross; Rami Rahal; Nicolas Stransky; Christoph Lengauer; Klaus P Hoeflich
Journal:  J Clin Invest       Date:  2015-05-01       Impact factor: 14.808

7.  Obama's Precision Medicine Initiative.

Authors:  Sharon F Terry
Journal:  Genet Test Mol Biomarkers       Date:  2015-03

8.  Hotspots of Aberrant Enhancer Activity in Fibrolamellar Carcinoma Reveal Candidate Oncogenic Pathways and Therapeutic Vulnerabilities.

Authors:  Timothy A Dinh; Ramja Sritharan; F Donelson Smith; Adam B Francisco; Rosanna K Ma; Rodica P Bunaciu; Matt Kanke; Charles G Danko; Andrew P Massa; John D Scott; Praveen Sethupathy
Journal:  Cell Rep       Date:  2020-04-14       Impact factor: 9.423

9.  [Hepatocellular carcinomas and their mimics].

Authors:  H-P Fischer; D Goltz
Journal:  Pathologe       Date:  2019-02       Impact factor: 1.011

Review 10.  Functional and genetic deconstruction of the cellular origin in liver cancer.

Authors:  Jens U Marquardt; Jesper B Andersen; Snorri S Thorgeirsson
Journal:  Nat Rev Cancer       Date:  2015-11       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.